BioSpace News Archive

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced additional results from the landmark DREAM-HF randomized controlled Phase 3 trial in 537 treated patients with chronic heart failure with reduced left ventricular ejection fraction who received rexlemestrocel-L or control sham.

Humanigen, Inc. and EVERSANA announced that they are partnering to make lenzilumab available to hospitalized and hypoxic COVID-19 patients in the event that an Emergency Use Authorization is issued from the U.S.

Expects continued strong financial and operating momentum in 2021, forecasting total revenues of $2 billion at the midpoint and Adjusted EBITDA of $780 million at the midpoint, both increases year-over-year

Atara has had productive interactions with the FDA for ATA188 and is progressing the Phase 2 randomized clinical trial (RCT) toward an interim analysis in H1 2022

Hutchison China MediTech Limited and Inmagene Biopharmaceuticals announce a strategic partnership to further develop four novel preclinical drug candidates discovered by Chi-Med for the potential treatment of multiple immunological diseases.

STAAR Surgical Company, a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, provided preliminary results for the fourth quarter and fiscal year ended January 1, 2021.

Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, will provide an update on Vision 3x3 and the company’s 2021 key milestones at the 39th Annual J.P. Morgan Healthcare Conference.

On January 8, 2021, Shenzhen Chipscreen Biosciences Co., Ltd. submitted its pivotal phase III clinical trial application of national class I innovative drug Chiauranib to NMPA, for the treatment of Small Cell Lung Cancer as a single agent for the patients after 2nd-line systemic chemotherapy and recurrence afterwards.